Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 13/20 | 1.00 |
| ▸ | TACR1 | P25103 | 12/20 | 0.46 |
| ▸ | TACR2 | P21452 | 3/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.38 |
| ▸ | UBE2M | P61081 | 2/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296877 | 0.94 | TACR3 (0.89) | TACR3TACR1TACR2CCR5 | |
| SCHEMBL295666 | 0.93 | TACR3 (0.86) | TACR3TACR1TACR2DCUN1D1KCNH2 | |
| SCHEMBL8049953 | 0.93 | TACR3 (0.86) | TACR3TACR1TACR2DCUN1D1KCNH2 | |
| SCHEMBL13907247 | 0.89 | TACR3 (0.81) | TACR3TACR1TACR2CCR5KCNH2 | |
| SCHEMBL12906870 | 0.89 | TACR3 (0.81) | TACR3TACR1TACR2CCR5KCNH2 | |
| SCHEMBL12906871 | 0.89 | TACR3 (0.81) | TACR3TACR1TACR2CCR5KCNH2 | |
| SCHEMBL12906866 | 0.89 | TACR3 (0.81) | TACR3TACR1TACR2CCR5KCNH2 | |
| SCHEMBL297436 | 0.89 | TACR3 (0.81) | TACR3TACR1TACR2CCR5KCNH2 | |
| SCHEMBL297336 | 0.89 | TACR3 (0.81) | TACR3TACR1TACR2CCR5KCNH2 | |
| SCHEMBL296656 | 0.87 | TACR3 (0.77) | TACR3TACR1TACR2DCUN1D1UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | claimed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | claimed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | claimed |
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | TACR3 95/4885TACR1 26/4885TACR2 21/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | TACR3 95/4885TACR1 26/4885TACR2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.